OpenAI Watch posted an update
OpenAI-backed Red Queen Bio has raised $36 million to use AI to design antibody drugs against novel pathogens, according to The Wall Street Journal. The startup says its work is aimed at threats that could include pathogens created by future AI systems, placing defensive drug design in a striking new part of the AI biosecurity debate.
Why it mattersThe Journal’s Georgia Wells reports that the company is using AI to design antibodies before such threats emerge. That makes this more than a general AI investment story: it is a concrete attempt to apply AI to counter a risk associated with future AI capabilities. The report does not establish that the drugs have been developed or tested against an actual AI-enabled pathogen. Antibody design is a practical line of defence to watch, but the gap between designing a candidate and showing it works is rather important.
Discuss: What evidence should Red Queen Bio publish before this counts as a credible biosecurity safeguard, rather than an ambitious pitch?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.